Tori Guidry
Family · Thibodaux, LANPI 1497497119
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $298 of the $398 with a category attached, or 74.9%. 10 manufacturers reported payments, led by Astellas Pharma US Inc at 25.1% of the total. Reporting peaked in 2022 at $291 and has fallen 90.5% since, to $28 in 2025. That places this record below the midpoint for family clinicians in LA, where the typical reported total is $521.
Across 17 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$100
- Otsuka America Pharmaceutical, Inc.$73
- Bayer$52
- Alkermes, Inc.$42
- AbbVie$39
- Neurocrine Biosciences, Inc.$26
- plus $65 from 4 others
What the payments were for
- Food & beverage$29875%
- Education$10025%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 1 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Bayer | 3 | $52 |
| Alkermes, Inc. | 2 | $42 |
| AbbVie | 2 | $39 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Dexcom, Inc. | 1 | $22 |
| UCB, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$398 in reported general payments places this provider in the 40th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 21 | $16,027 |
| GemtesaVibegron | 52 | $12,923 |
| FarxigaDapagliflozin Propanediol | 30 | $8,724 |
| EliquisApixaban | 20 | $5,795 |
| EntrestoSacubitril/Valsartan | 13 | $4,453 |
| Ondansetron Hcl | 27 | $730 |
| Alprazolam | 33 | $668 |
| Pregabalin | 16 | $470 |
| Sertraline Hcl | 30 | $437 |
| Levothyroxine Sodium | 26 | $403 |
| Megestrol Acetate | 20 | $307 |
| Allopurinol | 22 | $293 |
| Cyclobenzaprine Hcl | 24 | $266 |
| Potassium Chloride | 16 | $251 |
| Buspirone Hcl | 19 | $189 |
Paid to pharmacies, not to this prescriber.
Other family in Thibodaux
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.